QT Imaging Reports Preliminary Financial Results for 2025

Written by Emily J. Thompson, Senior Investment Analyst

Source: Businesswire

Updated: 2 days ago

0mins

QTI-9.14%

Should l Buy QTI?

Source: Businesswire

Record Quarterly Revenue: QT Imaging achieved a record revenue of $8.275 million in Q4 2025, significantly up from $847,000 in the same quarter last year, indicating strong market demand and execution in breast health management.
Annual Performance Exceeds Expectations: The company reported total revenue of $18.925 million for the full year 2025, surpassing its projections and reflecting a successful transition from a traditional scanner company to a SaaS and biomarker-driven medical imaging platform.
2026 Sales Outlook: QT Imaging anticipates approximately $39 million in revenue for 2026, including scanner shipments and initial SaaS Cloud Platform revenue, highlighting the strategic partnership with NXC Imaging and its potential to drive future growth.
Investor Call Announcement: The company plans to hold an investment community conference call on March 23, 2026, following the filing of its Form 10-K for 2025, enhancing communication with investors and showcasing its future growth strategy and financial transparency.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy QTI?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on QTI

Wall Street analysts forecast QTI stock price to rise

0 Analyst Rating

0 Buy

0 Hold

0 Sell

Current: 5.800

Low

Averages

High

Current: 5.800

Low

Averages

High

Lake Street

NULL

Buy

initiated

$10

2026-01-30

Reason

Lake Street

Price Target

$10

AI Analysis

2026-01-30

initiated

NULL

Buy

Reason

Lake Street initiated coverage of QT Imaging with a Buy rating and $10 price target. The company's QT Scan delivers true 3D imaging of breast tissue and offers unique characteristics, making it highly attractive to patients and clinicians, the analyst tells investors. The "massive homerun opportunity" for QT is to become a significant modality within breast cancer screening, the analyst added.

About QTI

QT Imaging Holdings, Inc. is a medical device company engaged in the research, development, and commercialization of body imaging systems using low-frequency sound waves. The Company's products include QTI Breast Acoustic CT Scanner and QTviewer Software. QTI’s Breast Acoustic CT scanner with QTViewer viewer software is the only three-dimensional (3D) imaging device to receive United States Food and Drug Administration (FDA) clearance for use as a transmission and reflection ultrasonic imaging system of a patients breast. QTviewer is its proprietary image viewing and analysis platform, purpose-built to interpret the rich, quantitative datasets generated by the QTI Breast Acoustic CT™ scanner. The QTviewer allows users to rotate, zoom, and cross-navigate entire breast volumes. Whether isolating lesions or exploring architectural distortion, radiologists can interact with the data dynamically to gain an understanding of tissue structure and lesion morphology.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

QT Imaging Reports Record $8.3 Million Revenue in Q4 2025

2 days agoNewsfilter

Significant Revenue Growth: In Q4 2025, QT Imaging achieved record revenue of $8.3 million, representing a 97% increase from Q3 2025 and an impressive 877% year-over-year growth, highlighting strong market demand and execution in the medical imaging sector.
Record Shipment Volume: The company shipped 17 QT Breast Acoustic CT™ scanners in Q4 2025, totaling 40 units for the year, a substantial increase from 12 units shipped in 2024, indicating enhanced market acceptance and sales capability of its products.
Successful Nasdaq Relisting: QT Imaging successfully relisted on Nasdaq in less than a year after leaving the OTCQB market, demonstrating compliance in financial and corporate governance, which boosts investor confidence and enhances market visibility.
Strategic Collaboration Expansion: The company entered into a strategic partnership with Intelerad Medical Systems, facilitating seamless integration of QT Imaging's cloud SaaS platform with Intelerad's secure cloud platform, further strengthening its competitive position in medical imaging solutions.

QT Imaging Reports Q4 Loss but 2025 Revenue Surpasses Guidance

1 day agoseekingalpha

Significant Revenue Growth: QT Imaging reported a revenue of $18.9 million for 2025, exceeding the company's guidance of $18 million and representing a remarkable 288% increase compared to 2024, indicating strong market performance and growth potential.
Decline in Gross Margin: The gross margin for 2025 was 45%, down from 54% in 2024, primarily due to higher costs associated with two scanners built by a contract manufacturing partner, including tariffs and fees, which may impact future profitability.
Improvement in Operating Expenses: Total operating expenses for 2025 were $13.0 million, a 12% improvement from $14.8 million in 2024, largely due to a $3.6 million decrease in professional fees, showcasing effective cost control measures by the company.
Widening Net Loss: The net loss for 2025 was $21.1 million, significantly higher than the $9.0 million loss in 2024, primarily driven by non-cash expenses and increases in fair value liabilities, reflecting challenges in financial management.